Abstract

The dopamine transporter (DAT) serves a critical role in controlling dopamine (DA)-mediated neurotransmission by regulating the clearance of DA from the synapse and extrasynaptic regions and thereby modulating DA action at postsynaptic DA receptors. Major drugs of abuse such as amphetamine and cocaine interact with DATs to alter their actions resulting in an enhancement in extracellular DA concentrations. We previously identified a novel allosteric site in the DAT and the related human serotonin transporter that lies outside the central orthosteric substrate- and cocaine-binding pocket. Here, we demonstrate that the dopaminergic psychostimulant sydnocarb is a ligand of this novel allosteric site. We identified the molecular determinants of the interaction between sydnocarb and DAT at the allosteric site using molecular dynamics simulations. Biochemical-substituted cysteine scanning accessibility experiments have supported the computational predictions by demonstrating the occurrence of specific interactions between sydnocarb and amino acids within the allosteric site. Functional dopamine uptake studies have further shown that sydnocarb is a noncompetitive inhibitor of DAT in accord with the involvement of a site different from the orthosteric site in binding this psychostimulant. Finally, DA uptake studies also demonstrate that sydnocarb affects the interaction of DAT with both cocaine and amphetamine. In summary, these studies further strengthen the prospect that allosteric modulation of DAT activity could have therapeutic potential.

Highlights

  • The dopamine transporter is a membrane-bound protein present in the presynaptic terminals of dopaminergic neurons in the central nervous system

  • The results presented in this paper provided strong empirical evidence that sydnocarb is an allosteric modulator of human DAT (hDAT) and that it could serve as a promising lead molecule for developing novel therapeutics against addiction

  • This study further supported the therapeutic relevance of engaging potential allosteric sites within the EC vestibular region of hDAT using small molecules

Read more

Summary

Introduction

The dopamine transporter is a membrane-bound protein present in the presynaptic terminals of dopaminergic neurons in the central nervous system. It belongs to the solute carrier 6 (SLC6) family of transporters and controls the signal amplitude and duration of dopaminergic neurotransmission by transporting extracellular (EC) dopamine (DA) from the synapse back into the presynaptic neuronal terminals [1]. DAT is known to be the primary site of action for several psychostimulants and recreational drugs, including cocaine, amphetamine, and methamphetamine. The stimulatory action of these drugs of abuse is caused by their interaction with DAT causing a blockade or reversal of DA transport, thereby resulting in an increase in synaptic dopaminergic levels and neurotransmission [2]. The successful application of such compounds have largely failed due, in part, to their own abuse

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call